XBI - Vertex: In A Class By Itself Promising Pipeline Of Game-Changing Drugs

• Vertex Pharma develops, manufactures, and commercializes small molecule drugs for patients with serious diseases. The company has obtained approval for several products that treat forms of cystic fibrosis ("CF").
• The firm’s drug pipeline includes treatments for sickle cell disease, beta-thalassemia, Type 1 diabetes, APOL1-mediated kidney diseases, pain management, and more.
• Unlike many other risky biotechs, Vertex Pharma's already-commercialized CF portfolio throws off tremendous amounts of free cash flow, and it has a strong net-cash-rich balance sheet to boot.
• In this article, we evaluate the potential of its various drug candidates and remain big fans of its partnership to develop CRISPR gene-editing technologies.
• We think Vertex Pharma's stock has tremendous potential upside, as it has both the capacity and financial wherewithal to drive investor returns higher via a unique pipeline that it continues to advance.

For further details see: